Ribera, Josep-Maria <br/><br/>
Adverse prognosis of bulky disease in good-risk DLBCL.  [electronic resource] 

 -  The Lancet. Oncology  May 2008 
 - 406-7 p.  digital 
<br/><br/> Publication Type: Comment; Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(08)70111-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Neoplasm Staging<br/>Patient Selection<br/>Prednisone--administration & dosage<br/>Prognosis<br/>Proportional Hazards Models<br/>Radiotherapy, Adjuvant<br/>Risk Assessment<br/>Rituximab<br/>Time Factors<br/>Treatment Outcome<br/>Vincristine--administration & dosage